Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Are we living inside a massive brain?

The human brain contains 86 billion neurons forming trillions of connections, giving rise to consciousness through complex interaction. On a vastly larger scale, the observable universe contains trillions of galaxies linked by cosmic filaments stretching tens of millions of light-years. Striking similarities between neural networks and the cosmic web raise a profound question: if awareness can emerge from complexity in the brain, what might emerge from complexity on a cosmic scale?

NASA smashed into an asteroid. Now Hera has revealed a strange new world

A European spacecraft has revealed a mysterious, crater-covered side of the asteroid Didymos as it prepares to investigate the aftermath of NASA’s historic 2022 asteroid impact. The mission could uncover new clues about the collision and help turn asteroid deflection into a powerful defense against future threats to Earth.

There could be trillions of tonnes of dark matter near the Moon, experts say

Although there’s evidence that dark matter forms vast halos around galaxies and clusters, while being sparse in enormous ‘voids’, there’s no reason to suppose dark matter doesn’t also exist on or around Earth.

In fact, one study suggests there are 24 trillion metric tonnes of dark matter lying between Earth and the Moon! Whether this is true or not is yet to be determined.

Could planets that orbit other stars be nonspherical?

Rich Livitski Seal Beach, California

Bodies large enough to be considered planets have enough mass that gravity molds them into a roughly spherical shape.

The key word here is roughly — other factors also come into play, such as a planet’s composition (rocky or gassy) and its rate of spin. The faster a planet spins, the more its rotation causes it to bulge outward at the equator. That’s because as a planet rotates, there’s a tug-of-war between the way material wants to fly off the planet due to rotation and the way gravity wants to pull all that planet’s material inward. The battle between these forces is most intense at the equator.

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation

The two essential requirements for pathologic specimens in the era of personalized therapies for non-small cell lung carcinoma (NSCLC) are accurate subtyping as adenocarcinoma (ADC) versus squamous cell carcinoma (SqCC) and suitability for EGFR molecular testing, as well as for testing of other oncogenes such as EML4-ALK and KRAS. Actually, the value of EGFR expressed in patients with NSCLC in predicting a benefit in terms of survival from treatment with an epidermal growth factor receptor targeted therapy is still in debate, while there is a convincing evidence on the predictive role of the EGFR mutational status with regard to the response to tyrosine kinase inhibitors (TKIs).

This is a literature overview on the state-of-the-art of EGFR oncogenic mutation in NSCLC. It is designed to highlight the preclinical rationale driving the molecular footprint assessment, the progressive development of a specific pharmacological treatment and the best method to identify those NSCLC who would most likely benefit from treatment with EGFR-targeted therapy. This is supported by the belief that a rationale for the prioritization of specific regimens based on patient-tailored therapy could be closer than commonly expected.

Pulsed radiation therapy for the treatment of newly diagnosed glioblastoma

The results of this prospective study demonstrate the feasibility and safety of PRT for the treatment of newly diagnosed GBM patients. To our knowledge, this is the first study to investigate the use of PRT prospectively and in the definitive management of this patient population. The observed clinical outcomes are promising and compare favorably with those of well-matched patients treated at our institution with SRT as well as to historic controls. The 4 largest randomized trials investigating various treatments for newly diagnosed GBM reported median PFS of 4 to 7.3 months and mOS of 14.6 to 16.1 months in patients receiving concurrent SRT and TMZ, compared with 10.7 and 20.9 months for patients receiving PRT and TMZ on our study.,,, Notably, the patient cohort in our study has a slightly higher median age and a higher percentage of patients with subtotal tumor resection compared with all of the aforementioned trials.

All but one of the patients in this study had IDH–WT tumors, and only 3 patients had MGMT methylated tumors. These tumor characteristics portend a poor prognosis. The reported mOS in patients with IDH–WT tumors is in the range of 12 to 15 months., In a recent randomized trial, which investigated the addition of TTF to maintenance TMZ, patients with MGMT unmethylated tumors receiving SRT and TMZ had mOS of 14.7 months. Even the addition of TTF, which has resulted in the highest mOS in GBM patients reported by any major randomized trial to date, did not drastically improve survival in patients with MGMT unmethylated tumors (mOS of 16.9 mo).

Maintenance of QoL and preservation of NCF are important endpoints of treatment, especially in patients with GBM given their poor prognosis and relatively short life span. There are a paucity of longitudinal data on QoL and NCF after definitive treatment in GBM patients. Nonetheless, the existing evidence shows NCF to be an independent predictor of survival in high-grade gliomas and has a strong direct correlation with QoL and the ability to maintain independence and perform daily living activities.29–32 There has been a concerted effort to minimize RT-related NCF, and recent studies have shown promising results in this regard with the addition of memantine and employment of RT techniques that deliberately avoid the hippocampus, which is central to preservation of NCF.33,34 Unfortunately, cognitive decline remains a common complication in long-term GBM survivors.